Bruker has announced the planned discontinuation of the IsoSpark and IsoLight platforms. Customers with questions about transition options and last-time-buy opportunities should contact their Bruker sales representative.
Explore IsoPlexis’ advanced immune-based approaches in systemic lupus erythematosus and adverse events like cytokine release syndrome and neurotoxicity in cell therapy
Determine correlates and drivers of adverse reactions using single-cell functional proteomics
Learn how these biomarkers may improve therapeutic development and intervention
